Valuation: Guided Therapeutics Inc

Market Cap 26.55M 23.29M 21.57M 19.85M 37.45M 2.55B 37.93M 257M 101M 1.25B 99.66M 97.51M 4.33B P/E 2024
-3x
P/E 2025 -12.7x
Enterprise Value 29.42M 25.81M 23.91M 22M 41.51M 2.83B 42.04M 285M 112M 1.39B 110M 108M 4.8B EV / Sales 2024
1,649x
EV / Sales 2025 64.4x
Free-Float
63.48%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 70 05/03/2023
Chief Tech/Sci/R&D Officer 70 01/12/2010
Director TitleAgeSince
Director/Board Member 70 30/11/2016
Director/Board Member 76 09/04/2006
Chairman 67 30/09/2013
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%-0.96%+26.21%-2.75% 196B
-10.99%-10.57%-5.81%-26.75% 142B
-0.88%-14.02%-32.50%+0.69% 125B
-1.33%-3.27%-58.33%-19.21% 65.06B
-0.53%-7.89%+10.54%-8.74% 48.94B
-2.38%-2.95%-25.16%-32.78% 44.9B
+2.00%-0.88%+16.55%+6.67% 36.79B
+2.80%-1.52%+27.83%+31.38% 35.11B
-1.41%-1.36%-24.08%-10.71% 28.65B
Average -1.26%-3.21%-7.19%-6.91% 80.27B
Weighted average by Cap. -2.25%-2.97%-4.54%-8.82%

Financials

2024 2025
Net sales 7K 6.14K 5.69K 5.23K 9.87K 674K 10K 67.88K 26.55K 330K 26.28K 25.71K 1.14M 767K 673K 623K 573K 1.08M 73.8M 1.1M 7.44M 2.91M 36.18M 2.88M 2.82M 125M
Net income -2.42M -2.12M -1.96M -1.81M -3.41M -233M -3.45M -23.44M -9.17M -114M -9.07M -8.88M -394M -3.2M -2.8M -2.6M -2.39M -4.51M -308M -4.57M -30.99M -12.12M -151M -12M -11.74M -521M
Net Debt 1.77M 1.55M 1.44M 1.32M 2.5M 170M 2.53M 17.17M 6.72M 83.55M 6.65M 6.5M 289M 2.88M 2.52M 2.34M 2.15M 4.06M 277M 4.11M 27.89M 10.91M 136M 10.8M 10.56M 469M
Logo Guided Therapeutics Inc
Guided Therapeutics, Inc. is a medical technology company. The Company is focused on developing medical devices that have the potential to improve healthcare. The Company’s primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.
Employees
-